Aslan has gained rights to develop and market BMS-777607 in Australia,China, Korea, Taiwan and other selected Asian countries while Bristol-Myers Squibb retains rights at the rest of the contries, under the signed agreement.
As per a pre-agreed development agreement, Aslan is set to develop BMS-777607 that will target gastric cancer and lung cancer.
Aslan CEO Carl Firth said this partnership demonstrates how a drug development company can work together with a global biopharmaceutical company to accelerate drug development and conduct early clinical studies in Asia.